Patient P-01328

Synthetic patientNBL-101 · Day 102 · 55–64 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 46 SC-12 recommended — Supportive Compound SC-12
Day 47 Patient accepted — Started SC-12 in the companion
Day 53 No meaningful change — Supportive Compound SC-12
Day 56 GI-04 recommended — GI Support Protocol GI-04
Day 57 Patient declined — Not now

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Toxicity-4
Treatment adherence-3
Nutritional resilience+2

What helped?

Supportive Compound SC-12Day 46
Result: no meaningful change
GI Support Protocol GI-04Day 56
Declined by patient

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 65 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
Autonomic recovery ↑45
- WearableResting HR 73 bpm
- Wearable3,914 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 45

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.7 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 6.9 h
Steps: 3,391
Resting HR: 74 bpm

Daily log: GI score 65, nutritional resilience 29, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01598	57%	S14	GI-04	no change	45
P-01751	53%	S14	ME-01	improved	48
P-01311	50%	S14	ME-01	improved	49
P-01675	50%	S14	NP-02	improved	38
P-01843	50%	S14	SC-12	no change	45
P-01887	50%	S12	ME-01	improved	43
P-01732	49%	S14	ME-01	improved	45
P-01782	49%	S14	NP-02	no change	48
P-01830	49%	S14	—	—	44
P-01564	48%	S14	ME-01	improved	39
P-01595	48%	S14	GI-04	no change	51
P-01834	48%	S14	NP-02	improved	44